|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.38 USD | -6.90% |
|
-31.83% | -1.91% |
| 31/07 | Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial | MT |
| 31/07 | Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -6.90% | -31.83% | -33.85% | -21.41% | -1.91% | +215.16% | +128.87% | -44.32% | - | 139.56Cr | |
| -0.36% | +2.23% | -0.78% | +16.90% | +4.17% | -2.06% | +12.54% | -21.58% | +209.16% | 4.85TCr | |
| -2.71% | -2.99% | -3.97% | +23.36% | +129.06% | +390.72% | +472.12% | +518.26% | - | 3.99TCr | |
| -0.71% | +9.45% | +13.30% | +45.00% | +3.53% | +27.69% | +7.89% | -6.65% | +202.91% | 3.87TCr | |
| -0.71% | -3.72% | +1.39% | +5.60% | +3.28% | +3.11% | +52.45% | -8.11% | +1,080.03% | 3.51TCr | |
| -2.41% | +2.59% | +3.17% | -4.58% | +5.70% | +11.68% | +41.16% | -15.90% | +153.21% | 2.98TCr | |
| -0.66% | -2.73% | +1.45% | +37.47% | +2.07% | +32.57% | +122.17% | +224.55% | - | 1.61TCr | |
| -0.19% | -3.93% | -9.13% | +6.44% | - | - | - | - | - | 1.61TCr | |
| -0.62% | +2.02% | -2.02% | +14.77% | +8.56% | +2.76% | +14.08% | -33.14% | +80.74% | 1.36TCr | |
| -3.15% | -6.14% | -7.33% | +41.48% | -13.07% | -3.88% | -36.90% | -35.10% | +108.76% | 1.26TCr | |
| +0.07% | +0.73% | +1.72% | +31.79% | +22.67% | +31.45% | -10.95% | -40.04% | +156.16% | 1.12TCr | |
| -0.71% | +2.93% | -0.24% | +33.98% | +15.74% | +37.49% | +14.55% | -43.86% | +168.58% | 1.12TCr | |
| +0.94% | -4.88% | -16.04% | +11.25% | -10.88% | +75.33% | +536.42% | +266.84% | +2,418.78% | 1.05TCr | |
| +0.01% | -0.13% | +0.46% | +60.51% | +77.68% | +260.12% | +534.99% | - | - | 1.01TCr | |
| -1.98% | -6.38% | +23.91% | +23.06% | +26.87% | +19.83% | +28.50% | -60.84% | - | 909.41Cr | |
| -3.19% | -2.42% | +0.59% | +32.92% | +51.45% | +145.74% | +612.33% | +168.53% | - | 878.75Cr | |
| +5.25% | -2.63% | -34.49% | -27.78% | -31.12% | +25.41% | +38.23% | +44.12% | +44.42% | 860.34Cr | |
| -0.75% | -3.26% | -2.55% | -9.51% | +3.65% | +497.98% | +1,973.22% | +37.43% | - | 858.19Cr | |
| +2.25% | +3.04% | +8.12% | +24.65% | -10.58% | -19.97% | -18.67% | -27.75% | +37.34% | 856.15Cr | |
| -2.99% | -8.85% | -12.59% | +20.00% | +28.92% | +129.75% | +320.06% | +67.18% | - | 850.54Cr | |
| Average | -0.86% | -2.33% | -3.44% | +18.30% | +16.62% | +98.99% | +254.90% | +54.98% | +423.64% | 1.73TCr | |
| Weighted average by Cap. | -0.76% | +0.53% | -0.32% | +20.11% | +22.56% | +87.31% | +185.02% | +78.21% | +406.20% |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
